Dublin, Oct. 10, 2017 -- The "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs.
TDM market is analyzed from 2016 to 2026 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 21 tables, 9 figures and 210 selected references from literature.
Benefits of this report
- Up-to-date one-stop information on therapeutic drug monitoring
- Description of 35 companies involved with their collaborations in this area
- Market analysis 2016-2026
- Market values in major regions
- Strategies for developing markets for therapeutic drug monitoring
- A selected bibliography of 210 publications
- Text is supplemented by 21 tables and 9 figures
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring
- Reference laboratories providing drug monitoring services
- Pharmaceutical companies interested in companion tests for monitoring their drugs
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information about this report visit https://www.researchandmarkets.com/research/hzksfx/therapeutic_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery


SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 



